tiprankstipranks
AdAlta Enhances Leadership and Progresses Key Strategies in Cellular Therapy and Anti-Fibrotic Drug Development
Company Announcements

AdAlta Enhances Leadership and Progresses Key Strategies in Cellular Therapy and Anti-Fibrotic Drug Development

Story Highlights

Invest with Confidence:

An announcement from AdAlta Ltd. ( (AU:1AD) ) is now available.

AdAlta Limited has strengthened its leadership with new board members and a clinical advisory team to support its growth strategy. The company has signed its first non-binding term sheet for its ‘East to West’ cellular therapy strategy and continues to enhance its AD-214 anti-fibrotic drug candidate’s value, aiming to secure partnerships and financing for further development.

More about AdAlta Ltd.

AdAlta Limited is a developer of next-generation protein and cell therapeutic products, focusing on the rapidly growing cellular immunotherapy market and anti-fibrotic drugs. The company operates primarily in the biotechnology sector, aiming to bring Asian cellular therapy innovations to Western markets and developing therapeutics for fibrotic diseases.

YTD Price Performance: -15.00%

Average Trading Volume: 350,569

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$10.73M

See more insights into 1AD stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App